Neurocrine Biosciences
NBIX
#1318
Rank
A$24.55 B
Marketcap
A$244.19
Share price
2.64%
Change (1 day)
27.18%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2026 (TTM): A$1.19 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are A$3.10 Billion. In 2025 the company made an earning of A$0.92 Billion, an increase over its 2024 earnings that were of A$0.88 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.19 B29.28%
2025 A$0.92 B3.9%
2024 A$0.88 B96.41%
2023 A$0.45 B41.13%
2022 A$0.32 B73.74%
2021 A$0.18 B-8.82%
2020 A$0.20 B77.78%
2019 A$0.11 B49.83%
2018 A$75.88 M-142.57%
2017 -A$0.18 Billion-14.73%
2016 -A$0.21 Billion53.15%
2015 -A$0.14 Billion46.25%
2014 -A$93.34 Million29.66%
2013 -A$71.99 Million-3530.8%
2012 A$2.09 M-95.73%
2011 A$49.15 M
2009 -A$69.1 Million-45.38%
2008 -A$0.13 Billion-58.87%
2007 -A$0.31 Billion87.3%
2006 -A$0.17 Billion351.97%
2005 -A$36.33 Million-52.09%
2004 -A$75.84 Million-10.98%
2003 -A$85.19 Million
2001 -A$63.59 Million
1999 -A$28.68 Million108.32%
1998 -A$13.77 Million
1996 A$4.2 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
A$15.34 B 1,225.86%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$9.55 B 725.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$45.10 B 3,796.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$0.12 B-89.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-A$60.52 Million-105.23%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$0.13 B-88.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-A$6.95 Million-100.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.45 B 112.21%๐Ÿ‡ฌ๐Ÿ‡ง UK